Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

REHOVOT, Israel, March 14, 2019 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage antibody immunotherapy company leveraging a novel mimitope approach for antibody generation, today announced that it will present a scientific poster featuring the unique properties of a novel CTLA-4 antibody at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held at the Georgia World Congress Center in Atlanta, GA on Friday, March 29, 2019 – Wednesday, April 3, 2019.

The poster titled “A CTLA4 antibody with enhanced properties” will feature TikAb, a full human CTLA-4 antibody, and in-vitro and in-vivo assay results with comparative data to the existing treatment will be presented.

Title: A CTLA-4 antibody with enhanced properties
Date: Tuesday, April 2, 2019
Time: 8:00am – 12:00pm ET
Session: Immune Checkpoints 1
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24

Additional abstract information is available here: https://www.abstractsonline.com/pp8/#!/6812/presentation/2667

About Tikcro Technologies
Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro’s website at www.tikcro.com.

View original content:http://www.prnewswire.com/news-releases/tikcro-technologies-to-present-unique-properties-of-a-novel-ctla-4-antibody-at-the-aacr-annual-meeting-2019-in-the-us-300812028.html

SOURCE Tikcro Technologies Ltd.

Company Codes: OTC-PINK:TIKRF, OTC-QB:TIKRF